HIV-1 infection is associated with progressive and ultimately profound immunosuppression, resulting in the development of opportunistic infections and neoplasm in the later stage of illness. Despite strong virus-specific humoral and cellular responses, disease progression ensues in the vast majority of infected persons indicating that the immune responses are incapable of clearing the infection. Virus-specific CD4+ T helper lymphocytes are critical to maintain effective immunity in a number of chronic viral infections, but are characteristically weak or undetectable in chronic HIV-1 infection representing the most notable defect in the immunological repertoire against HIV-1. A better understanding of HIV-1-specific lymphocyte proliferative responses is likely to be highly relevant to understanding the immunopathogenesis of HIV-1 and may provide valuable insight into therapeutic interventions and vaccine development. The goals of this proposal are to determine the breadth, magnitude, specificity, and immunological function of HIV-1-specific proliferative responses in persons infected with HIV-1. Additionally, to determine whether intervention with anti-retroviral therapy during primary HIV-1 infection that impact on the generation of virus-specific lymphocyte proliferative responses. Blood sample will be obtained from individuals with long-term non- progressive infection and from persons with primary HIV-1 infection and early seroconversion. CD4+ lymphocytes will be tested in standard lymphocyte proliferation assays to HIV-1 specific antigens. When responses are detected, in-depth immunological studies including cytokine and chemokine production, fine epitope specificity and HLA restriction will be performed using bulk and cloned cells. In persons with primary HIV-1, potent anti-retroviral therapy will be initiated and subjects will be monitored for the development of an HIV-specific lymphocyte proliferative response. The development of HIV-1 specific lymphocyte responses will be correlated HIV-1 plasma, RNA viral load, and the generation and maintenance of virus-specific cytotoxic T lymphocyte activity. Insight into the immunological function of CD4+ HIV-1 specific lymphocytes may provide valuable information for immunotherapeutic and vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08AI001541-01
Application #
2650008
Study Section
Acquired Immunodeficiency Syndrome Research Review Committee (AIDS)
Project Start
1998-04-01
Project End
2001-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kawai, Tatsuo; Cosimi, A Benedict; Sachs, David H (2011) Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant 16:366-71
Montefiori, David C; Altfeld, Marcus; Lee, Paul K et al. (2003) Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol 170:3906-14
Goulder, P J; Altfeld, M A; Rosenberg, E S et al. (2001) Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 193:181-94
Goulder, P J; Addo, M M; Altfeld, M A et al. (2001) Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by elispot and intracellular cytokine staining assays. J Virol 75:1339-47
Montefiori, D C; Hill, T S; Vo, H T et al. (2001) Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 75:10200-7
Goulder, P J; Pasquier, C; Holmes, E C et al. (2001) Mother-to-child transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence variation. Immunol Lett 79:109-16
Norris, P J; Sumaroka, M; Brander, C et al. (2001) Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones. J Virol 75:9771-9
Brown, A J; Precious, H M; Whitcomb, J M et al. (2000) Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 74:10269-73
Little, S J; Daar, E S; D'Aquila, R T et al. (1999) Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-9